摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3-chlorophenyl)(furan-3-yl)methanone | 949934-39-8

中文名称
——
中文别名
——
英文名称
(3-chlorophenyl)(furan-3-yl)methanone
英文别名
(3-chlorophenyl)(3-furyl)methanone;(3-chlorophenyl)-(furan-3-yl)methanone
(3-chlorophenyl)(furan-3-yl)methanone化学式
CAS
949934-39-8
化学式
C11H7ClO2
mdl
——
分子量
206.628
InChiKey
NQDWNGXJGFZMPU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    (3-chlorophenyl)(furan-3-yl)methanone咪唑 作用下, 以 乙醚N,N-二甲基甲酰胺 为溶剂, 反应 1.0h, 生成 rac-[1-(3-chlorophenyl)-1-(3-furyl)ethoxy](trimethyl)silane
    参考文献:
    名称:
    [EN] HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
    [FR] COMPOSÉS HÉTÉROARYLE UTILES EN TANT QU'INHIBITEURS DE L'ENZYME D'ACTIVATION SUMO
    摘要:
    公开了公式(I)的化合物或其药物可接受的盐; 其中Y、Ra、Ra'、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值,并且星号位置表示的立体化学配置指示绝对立体化学。 根据本公开的化学实体可用作Sumo激活酶(SAE)的抑制剂。 进一步提供了包含本公开化合物的药物组合物以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或病症的方法。
    公开号:
    WO2016004136A1
  • 作为产物:
    描述:
    rac-(3-chlorophenyl)(3-furyl)methanol 在 二氧化锰 二氯甲烷乙酸乙酯 、 hexanes 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 以to give 1.60 g (90%) of the title compound as a white powder的产率得到(3-chlorophenyl)(furan-3-yl)methanone
    参考文献:
    名称:
    HETEROARYL COMPOUNDS USEFUL AS INHIBITORS OF SUMO ACTIVATING ENZYME
    摘要:
    本发明涉及化学实体,其为以下式(I)的化合物或其药学上可接受的盐;其中,Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1和Z2具有本文所述的值,并在星号位置描绘的立体化学构型表示绝对立体化学。根据本发明的化学实体可用作Sumo激活酶(SAE)的抑制剂。进一步提供了包括本发明化合物的制药组合物以及使用这些组合物治疗增生性、炎症性、心血管和神经退行性疾病或疾患的方法。
    公开号:
    US20160009744A1
点击查看最新优质反应信息

文献信息

  • Heteroaryl compounds useful as inhibitors of sumo activating enzyme
    申请人:Millennium Pharmaceuticals, Inc.
    公开号:US10335410B2
    公开(公告)日:2019-07-02
    Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    所公开的化学实体为式(I)化合物: 或其药学上可接受的盐;其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值,星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶(SAE)的抑制剂。进一步提供了包含本公开化合物的药物组合物,以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。
  • Heteroaryl compounds useful as inhibitors of SUMO activating enzyme
    申请人:Millennium Pharmaceuticals, Inc.
    公开号:US10780090B2
    公开(公告)日:2020-09-22
    Disclosed are chemical entities which are compounds of formula (I): or pharmaceutically acceptable salts thereof; wherein Y, Ra, Ra′, Rb, Rc, X1, X2, X3, Rd, Z1, and Z2 have the values described herein and stereochemical configurations depicted at asterisked positions indicate absolute stereochemistry. Chemical entities according to the disclosure can be useful as inhibitors of Sumo Activating Enzyme (SAE). Further provided are pharmaceutical compositions comprising a compound of the disclosure and methods of using the compositions in the treatment of proliferative, inflammatory, cardiovascular, and neurodegenerative diseases or disorders.
    所公开的化学实体为式(I)化合物: 或其药学上可接受的盐;其中 Y、Ra、Ra′、Rb、Rc、X1、X2、X3、Rd、Z1 和 Z2 具有本文所述的值,星号位置描述的立体化学构型表示绝对立体化学。根据本公开的化学实体可用作苏木活化酶(SAE)的抑制剂。进一步提供了包含本公开化合物的药物组合物,以及使用该组合物治疗增殖性、炎症性、心血管和神经退行性疾病或紊乱的方法。
  • Clotrimazole Scaffold as an Innovative Pharmacophore Towards Potent Antimalarial Agents: Design, Synthesis, and Biological and Structure–Activity Relationship Studies
    作者:Sandra Gemma、Giuseppe Campiani、Stefania Butini、Gagan Kukreja、Salvatore Sanna Coccone、Bhupendra P. Joshi、Marco Persico、Vito Nacci、Isabella Fiorini、Ettore Novellino、Ernesto Fattorusso、Orazio Taglialatela-Scafati、Luisa Savini、Donatella Taramelli、Nicoletta Basilico、Silvia Parapini、Giulia Morace、Vanessa Yardley、Simon Croft、Massimiliano Coletta、Stefano Marini、Caterina Fattorusso
    DOI:10.1021/jm701247k
    日期:2008.3.13
    We describe herein the design, synthesis, biological evaluation, and structure-activity relationship (SAR) studies of an innovative class of antimalarial agents based on a polyaromatic pharmacophore structurally related to clotrimazole and easy to synthesize by low-cost synthetic procedures. SAR studies delineated a number of structural features able to modulate the in vitro and in vivo antimalarial activity. A selected set of antimalarials was further biologically investigated and displayed low in vitro toxicity on a panel of human and murine cell lines. In vitro, the novel compounds proved to be selective for free heme, as demonstrated in the beta-hematin inhibitory activity assay, and did not show inhibitory activity against 14-alpha-lanosterol demethylase (a fungal P450 cytochrome). Compounds 2, 4e, and 4n exhibited in vivo activity against P. chabaudi after oral administration and thus represent promising antimalarial agents for further preclinical development.
  • WO2007/104696
    申请人:——
    公开号:——
    公开(公告)日:——
  • US9683003B2
    申请人:——
    公开号:US9683003B2
    公开(公告)日:2017-06-20
查看更多